TY - JOUR AU - Lakatos, Péter AU - Földes, János AU - Nagy, Zsolt AU - Takács, István AU - Speer, Gábor AU - Horváth, Csaba AU - Mohan, S AU - Baylink, DJ AU - Stern, PH TI - Serum insulin-like growth factor-I, insulin-like growth factor binding proteins, and bone mineral content in hyperthyroidism. JF - THYROID J2 - THYROID VL - 10 PY - 2000 IS - 5 SP - 417 EP - 423 PG - 7 SN - 1050-7256 DO - 10.1089/thy.2000.10.417 UR - https://m2.mtmt.hu/api/publication/1335572 ID - 1335572 AB - The mechanism by which thyroid hormones promote bone growth has not yet been elucidated. In vitro, thyroid hormones stimulate insulin-like growth factor-I (IGF-I) production by osteoblasts, which is important for the anabolic effects of the hormone on bone. To determine whether the IGF-I/IGF binding protein (IGFBP) profile is affected when thyroid hormone production is altered in vivo, we studied 36 women who had recently been diagnosed with hyperthyroidism (age: 29-67 years; 19 with Graves' disease, 17 with toxic nodular goiter) and 36 age-matched healthy women as controls. Serum IGF-I, and its binding proteins (IGFBP-3, IGFBP-4, and IGFBP-5), as well as bone mineral density (BMD) at the lumbar spine, femoral neck, and radius midshaft were measured before and 1 year after antithyroid (methimazole) treatment. Serum IGF-I levels were significantly increased in the hyperthyroid patients before treatment (214 +/- 18.2 ng/mL vs. 145 +/- 21.3 ng/mL; p < 0.05). There was no difference in IGF-I levels of patients with Graves' disease and toxic nodular goiter. Serum IGF-I concentrations returned to normal after treatment with methimazole. Serum IGFBP-3 and IGFBP-4 values were significantly elevated in the hyperthyroid group before treatment (3960 +/- 220 ng/mL and 749.7 +/- 53.1 ng/mL vs. 2701 +/- 180 ng/mL and 489.9 +/- 32.4 ng/mL; p < 0.05 and p < 0.01, respectively) and were reduced to those of controls after treatment. Serum IGFBP-5 of hyperthyroid subjects was not different from that of controls either before or after therapy. Serum free thyroxine showed a positive correlation with serum levels of IGF-I (r = 0.73, p < 0.05), IGFBP-3 (r = 0.59, p < 0.05), and IGFBP-4 (r = 0.67, p < 0.05) but not IGFBP-5. BMD at the radius midshaft was significantly lower in hyperthyroid patients at the start of the study and showed a positive correlation with serum IGF-I (r = 0.58; p < 0.001) and a negative correlation with IGFBP-4 (r = -0.61; p < 0.05). Radius BMD showed a 7.2% increase in the hyperthyroid group after 1 year of methimazole treatment, and the correlation between BMD and serum IGF-I disappeared. Our data indicate that thyroid hormones may influence the IGF-I/IGFBP system in vivo in hyperthyroidism. The anabolic effects of increased levels of IGF-I may be limited in hyperthyroidism due to the increases of inhibitory IGFBPs that can counteract the anabolic effects and contribute to the observed net bone loss. LA - English DB - MTMT ER - TY - JOUR AU - Balazs, C AU - Kiss, E AU - Vamos, A AU - Molnár, Ildikó AU - Farid, NR TI - Beneficial effect of pentoxifylline on thyroid associated ophthalmopathy (TAO)*: a pilot study. JF - JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM J2 - J CLIN ENDOCR METAB VL - 82 PY - 1997 IS - 6 SP - 1999 EP - 2002 PG - 4 SN - 0021-972X UR - https://m2.mtmt.hu/api/publication/2568530 ID - 2568530 AB - We have previously found that pentoxifylline (Ptx) inhibited cytokine induced HLA-DR expression and glycosaminoglycan (GAG) synthesis by retroorbital fibroblasts. We have now tested the clinical efficacy of Ptx in treating TAO. Ten patients with moderately severe ophthalmopathy were selected for study. All patients were euthyroid before and during the 12 weeks of the Ptx therapy. Serum GAG, TNF-alpha, anti-TSH-receptor, anti-eye muscle, anti-thyroglobulin and anti-thyroid peroxidase antibodies were determined sequentially. At the end of 12 weeks eight of the ten patients showed improvement in soft tissue but not in proptosis or extraocular muscle involvement. At baseline the levels of GAG (5.2+/-0.92 mg/dl v.s. 0.7+/-0.14 mg/dl, p<0.001) and TNF-alpha (33.6+/-6.6 pg/ml v.s. 5.4+/-1.3 pg/ml, p<0.001) were increased in patients compared to controls. They gradually decreased in the eight patients who responded to Ptx: after 4, 8 and 12 weeks of therapy serum GAG was 3.4+/-0.42 mg/dl, 2.5+/-0.77 mg/dl (p<0.01) and 1.1+/-0.2 mg/dl (p<0.001), respectively and serum TNF-alpha was 20.9+/-4.8 pg/ml, 14.9+/-2.2 pg/ml (p<0.05) and 9.7+/-1.8 pg/ml (p<0.01), respectively. Serum GAG and TNF alpha did not fall in the two patients who did not respond. The titre of anti-eye muscle antibodies but not anti-thyroid antibodies were lower at 12 weeks. Ptx has a beneficial effect on inflammatory symptoms of TAO and associated laboratory parameters in the majority of patients. LA - English DB - MTMT ER - TY - JOUR AU - Lakatos, Péter AU - Földes, János AU - Horváth, Csaba AU - Kiss, L AU - Tatrai, A AU - Takács, István AU - Tarjan, G AU - Stern, P H TI - Serum interleukin-6 and bone metabolism in patients with thyroid function disorders JF - JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM J2 - J CLIN ENDOCR METAB VL - 82 PY - 1997 IS - 1 SP - 78 EP - 81 PG - 4 SN - 0021-972X DO - 10.1210/jcem.82.1.3641 UR - https://m2.mtmt.hu/api/publication/1802122 ID - 1802122 N1 - Összes idézések száma a WoS-ban: 0 1st Department of Medicine, Semmelweis University Medical School, Budapest, H-1083, Hungary Hetenyi Geza County Hospital, Szolnok, H-5000, Hungary Dept. Molec. Pharmacol. Biol. Chem., NW University Medical School, Chicago, IL 60611, United States 1st Department of Medicine, Semmelweis University Medical School, Koranyi 2/A, Budapest, H-1083, Hungary Cited By :72 Export Date: 13 March 2020 CODEN: JCEMA Correspondence Address: Lakatos, P.; 1st Department of Medicine, Semmelweis University Medical School, Koranyi 2/A, Budapest H-1083, Hungary Chemicals/CAS: Amino Acids; deoxypyridinoline, 90032-33-0; Interleukin-6; Osteocalcin, 104982-03-8 AB - To determine the possible involvement of interleukin-6(IL-6) in the bone loss of hyperthyroidism, relationships between thyroid status, biochemical and densitometric parameters of bone metabolism, and IL-6 were studied in female subjects. Patients with hyperthyroidism caused by either toxic nodular goiter or Graves' disease had significantly higher serum IL-6 concentrations than normal controls. Within the control group, serum IL-6 was higher in postmenopausal than in premenopausal women, but this influence of menopausal status was not seen in the hyperthyroid patients. The production of IL-6 by blood mononuclear cells was higher in cells from the hyperthyroid women. Bone turnover was increased in the hyperthyroid patients based on serum osteocalcin and urinary deoxypyridinoline excretion, and the hyperthyroid group also had reduced radius bone mineral content (BMC). A subgroup of hyperthyroid patients who had the lowest BMC (values more than 1 SD below normal age-matched controls) also had serum IL-6 concentrations significantly greater than those of hyperthyroid patients showing less reduction of BMC. The correlations observed in this study support the possibility that IL-6 plays a role in mediating the bone loss that results from excess thyroid hormone. LA - English DB - MTMT ER - TY - JOUR AU - Molnár, Ildikó AU - Balazs, C TI - High circulating IL-6 level in Graves' ophthalmopathy. JF - AUTOIMMUNITY J2 - AUTOIMMUNITY VL - 25 PY - 1997 IS - 2 SP - 91 EP - 96 PG - 6 SN - 0891-6934 DO - 10.3109/08916939708996275 UR - https://m2.mtmt.hu/api/publication/2568531 ID - 2568531 AB - IL-6 is a paracrine and autocrine cytokine, which acts in the regulation of immunological and inflammatory processes. Its production can be observed in different cell types, as well as thyrocytes. The purpose of the study was to examine the serum IL-6 levels between the patients with Graves' disease (N = 47) and without (N = 29) ophthalmopathy in respect of the presence of inflammatory eye signs and thyroiditis, thyroid function and radioiodine or medical treatments. The serum IL-6 levels were greater (P < 0.025) in the patients with ophthalmopathy (440 +/- 32.4 pg/ml) than in those without eye disease (81.6 +/- 25.2 pg/ml). An elevated serum IL-6 levels could be detected in 22 out of 47 patients with ophthalmopathy with longer manifestation of thyroid disease than one year in comparison with those who had shorter (694 +/- 35.3 pg/ml vs 215.8 +/- 27.9 pg/ml, P < 0.05). The increase showed a strong association with the inflammatory signs of eye disease in the patients with Graves' hyperthyroidism compared with those without ophthalmopathy (513.3 +/- 33.7 pg/ml vs 96.9 +/- 12.1 pg/ml, P < 0.025). Euthyroid function and the presence of thyroiditis did not influence the serum IL-6 levels. Radioiodine and medical treatments did not lead to a remarkable decrease in the serum IL-6 levels. The results supported that IL-6 cytokine may be an important factor in the inflammatory events of Graves' ophthalmopathy. LA - English DB - MTMT ER -